Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
HALFAN vs ARTESUNATE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
HALFAN (halofantrine) is an antimalarial agent that acts as a blood schizonticide. It is thought to inhibit the polymerization of heme into hemozoin, leading to toxic accumulation of free heme within the parasite's food vacuole. It may also interfere with nucleic acid synthesis.
Artesunate is a water-soluble artemisinin derivative that produces rapid parasite clearance. It is converted in vivo to dihydroartemisinin, which generates free radicals that alkylate and damage parasite proteins, particularly targeting the sarcoplasmic/endoplasmic reticulum calcium ATPase (SERCA) of Plasmodium species.
Treatment of mild to moderate acute malaria caused by Plasmodium falciparum and Plasmodium vivax (including chloroquine-resistant strains)
Severe malaria (parenteral therapy),Uncomplicated malaria (combination therapy with other antimalarials),Off-label: Treatment of chloroquine-resistant falciparum malaria
Adults: 500 mg orally once daily.
2.4 mg/kg IV at 0, 12, 24, and 48 hours, then daily until oral therapy can be initiated.
Terminal elimination half-life is 10-18 hours (mean 14 hours) in healthy adults, allowing twice-daily dosing.
Terminal elimination half-life of artesunate is approximately 1 hour. The active metabolite dihydroartemisinin has a half-life of 1-2 hours. This short half-life supports rapid parasite clearance in severe malaria.
Halofantrine is extensively metabolized in the liver, primarily via cytochrome P450 (CYP) 3A4, to its active metabolite N-desbutylhalofantrine. Both parent drug and metabolite are highly bound to plasma proteins.
Primarily hydrolyzed in the stomach and in plasma by esterases to dihydroartemisinin (DHA), the active metabolite. DHA undergoes glucuronidation via UGT1A9 and UGT2B7.
Primarily hepatic metabolism; renal excretion of metabolites accounts for <10% unchanged drug; biliary/fecal elimination of metabolites approximately 20-30%.
Primarily hepatic metabolism; renal excretion of metabolites accounts for <10% as unchanged drug. Biliary/fecal elimination is minimal. ~80% of the dose is recovered in urine as metabolites, mainly dihydroartemisinin.
25-30% bound to serum albumin.
Artemisinin derivatives: ~93% bound to serum proteins, primarily albumin and alpha-1-acid glycoprotein.
0.9-1.0 L/kg, indicating distribution into total body water.
Vd approximately 0.6-0.8 L/kg, indicating distribution into total body water. Higher Vd in severe malaria due to increased capillary permeability.
Oral: 88-95%; rectal: 80-90%; intramuscular: 96%.
Oral: ~40% (range 20-50%) due to first-pass metabolism. Rectal: ~40-60%. IV: 100%.
GFR 30-50 m L/min: 250 mg once daily; GFR <30 m L/min: 125 mg once daily.
No dose adjustment required for any degree of renal impairment.
Child-Pugh A: no adjustment; Child-Pugh B: 250 mg once daily; Child-Pugh C: not recommended.
No dose adjustment required for Child-Pugh A or B; caution in Child-Pugh C due to limited data.
10 mg/kg orally once daily; maximum 500 mg/day.
2.4 mg/kg IV at 0, 12, 24, and 48 hours; weight-based (minimum 2.4 mg/kg per dose).
No specific adjustment; monitor renal function due to age-related decline.
No specific dose adjustment; use same dosing as adults with monitoring for adverse effects.
Cardiotoxicity: HALFAN prolongs the QT interval and can cause serious, life-threatening ventricular arrhythmias (e.g., torsade de pointes). Do not use in patients with pre-existing QTc prolongation, electrolyte disturbances (e.g., hypokalemia, hypomagnesemia), or those taking other drugs that prolong the QT interval. ECG monitoring is required before, during, and after therapy.
None.
Cardiotoxicity: QTc interval prolongation; contraindicated in patients with conduction disorders or concurrent QT-prolonging drugs.,Hematologic: May cause hemolysis in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency.,Gastrointestinal: Nausea, vomiting, diarrhea, abdominal pain.,Hepatic: Use with caution in hepatic impairment.,Pregnancy: Not recommended (teratogenic in animal studies).,Drug interactions: Avoid with CYP3A4 inhibitors and QT-prolonging agents.
Hemolysis: Cases of delayed hemolytic anemia have been reported, especially in patients with high parasitemia.,Cardiotoxicity: Theoretical risk of QT prolongation with co-administration of other QT-prolonging drugs.,Hypersensitivity: Severe allergic reactions (e.g., anaphylaxis) have occurred.
Pre-existing QTc prolongation or congenital long QT syndrome,History of ventricular arrhythmias,Hypokalemia or hypomagnesemia,Concurrent use of drugs that prolong the QT interval (e.g., class IA/III antiarrhythmics, some antibiotics, antipsychotics),G6PD deficiency (relative),Pregnancy and breastfeeding (contraindicated in pregnancy)
Hypersensitivity to artesunate, any artemisinin derivative, or any component of the formulation.,Pregnancy: Not recommended in first trimester unless life-threatening; avoid in second/third trimester if safer alternatives available.,Breastfeeding: Safety not established; discontinue breast-feeding or avoid drug.
Take with a high-fat meal (e.g., full yogurt, burger, nuts) to increase absorption by up to 10-fold. Grapefruit juice may increase halofantrine levels; avoid concurrent use. Avoid alcohol due to additive QT-prolonging effects.
No known significant food interactions. However, avoid grapefruit and grapefruit juice as they may alter drug metabolism (CYP2A6 inhibition). Maintain adequate hydration and nutrition to support recovery.
FDA Pregnancy Category C. Animal studies have shown embryotoxicity and teratogenicity at high doses. First trimester: Avoid use due to potential teratogenic effects. Second and third trimesters: Limited data; risk of fetal harm cannot be ruled out. Use only if potential benefit justifies risk.
Artesunate is contraindicated in the first trimester of pregnancy due to embryotoxicity and teratogenicity observed in animal studies. In the second and third trimesters, the benefit of treating life-threatening malaria generally outweighs risks, as untreated malaria poses significant fetal risks. However, the drug should be used with caution and only when clearly needed.
HALFAN is excreted in human milk. M/P ratio not reported. Due to potential for serious adverse reactions in nursing infants, decide whether to discontinue nursing or discontinue drug, taking into account importance of drug to mother.
Artesunate is excreted into breast milk in small amounts. The M/P ratio is not well-established. While the American Academy of Pediatrics considers artesunate compatible with breastfeeding, caution is advised, especially in nursing preterm or jaundiced infants. The benefits of breastfeeding and the necessity of maternal treatment should be weighed.
No specific dosing adjustments recommended in pregnancy. Monitor for increased clearance and consider dose titration based on clinical response and side effects. Use lowest effective dose.
No dose adjustment is required for artesunate during pregnancy based on pharmacokinetic changes. However, intravenous artesunate is the recommended treatment for severe malaria in the second and third trimesters. Oral artesunate may be used for uncomplicated malaria, but caution is advised in the first trimester due to teratogenicity.
Halofantrine (Halfan) is reserved for chloroquine-resistant Plasmodium falciparum malaria due to risk of fatal cardiotoxicity (QT prolongation, ventricular arrhythmias). Must obtain baseline ECG and monitor QTc; contraindicated if QTc >450 ms, family history of sudden death, or concurrent use of other QT-prolonging drugs. Administer with fatty food to enhance absorption, but food content may increase risk of arrhythmias. Do not repeat therapy within 6 weeks due to cumulative toxicity.
Artesunate is the first-line therapy for severe malaria (WHO recommendation). Administer IV or IM; IV dose is 2.4 mg/kg at 0, 12, and 24 hours then daily. Monitor for hypoglycemia and delayed hemolytic anemia (post-artesunate hemolysis). Not recommended for uncomplicated malaria due to risk of resistance. Artesunate is rapidly acting with a short half-life; always combine with a partner drug (e.g., artemether-lumefantrine) for complete cure. Do not use in first trimester of pregnancy unless life-threatening.
Take with a full meal high in fat to improve absorption.,Complete the full course even if symptoms improve.,Report immediately any chest pain, palpitations, fainting, or irregular heartbeat.,Avoid use with certain anti-malarials (e.g., quinine, mefloquine) and other drugs that affect heart rhythm.,Inform doctor if you have a personal or family history of heart problems, fainting, or electrolyte disturbances.,Do not use during pregnancy or breastfeeding unless specifically directed.
Take this medication exactly as prescribed; do not stop early even if you feel better.,You may experience temporary side effects such as dizziness, nausea, or fatigue; report any severe reactions.,This drug is used for severe malaria; you will likely be hospitalized for close monitoring.,Watch for signs of low blood sugar (sweating, confusion, rapid heartbeat) and report immediately.,Inform your healthcare provider about all medications you are taking, especially blood thinners or anti-seizure drugs.,Complete the full course of treatment, including any follow-up medications to prevent recurrence.
No interactions on record
"Nicotine, a known inducer of cytochrome P450 (CYP) enzymes, particularly CYP1A2 and possibly CYP2A6, may increase the hepatic metabolism of artesunate to its active metabolite dihydroartemisinin. This enhanced clearance can lead to subtherapeutic plasma concentrations of dihydroartemisinin, reducing the antimalarial efficacy of artesunate and potentially increasing the risk of treatment failure and the development of drug resistance."
"Amiodarone, a potent CYP3A4 and CYP2B6 inhibitor, can significantly reduce the systemic exposure of dihydroartemisinin, the active metabolite of artesunate. This occurs through inhibition of cytochrome P450 enzymes responsible for the conversion of artesunate to its active form, leading to decreased antimalarial efficacy. Clinically, this interaction may result in treatment failure or recrudescence of malaria when artesunate is co-administered with amiodarone."
"The coadministration of buprenorphine, a partial mu-opioid receptor agonist, with artesunate may reduce the systemic exposure of dihydroartemisinin (DHA), the primary active metabolite of artesunate, thereby decreasing antimalarial efficacy. This interaction is believed to occur through buprenorphine-mediated induction of cytochrome P450 (CYP) enzymes responsible for artesunate metabolism, leading to enhanced clearance and subtherapeutic concentration of DHA. Clinically, this could result in delayed parasite clearance and increased risk of treatment failure in malaria patients."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about HALFAN vs ARTESUNATE, answered by our medical review team.
HALFAN is a Antimalarial that works by HALFAN (halofantrine) is an antimalarial agent that acts as a blood schizonticide. It is thought to inhibit the polymerization of heme into hemozoin, leading to toxic accumulation of free heme within the parasite's food vacuole. It may also interfere with nucleic acid synthesis.. ARTESUNATE is a Antimalarial that works by Artesunate is a water-soluble artemisinin derivative that produces rapid parasite clearance. It is converted in vivo to dihydroartemisinin, which generates free radicals that alkylate and damage parasite proteins, particularly targeting the sarcoplasmic/endoplasmic reticulum calcium ATPase (SERCA) of Plasmodium species.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between HALFAN and ARTESUNATE depend on the specific clinical indication. These are both Antimalarial agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of HALFAN is: Adults: 500 mg orally once daily.. The standard adult dose of ARTESUNATE is: 2.4 mg/kg IV at 0, 12, 24, and 48 hours, then daily until oral therapy can be initiated.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between HALFAN and ARTESUNATE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. HALFAN is classified as Category C. FDA Pregnancy Category C. Animal studies have shown embryotoxicity and teratogenicity at high doses. First trimester: Avoid use due to potential teratogenic effects. Second and thi. ARTESUNATE is classified as Category C. Artesunate is contraindicated in the first trimester of pregnancy due to embryotoxicity and teratogenicity observed in animal studies. In the second and third trimesters, the benef. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.